FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Analysis of Cardiac Valvular Dysfunction with Use of Appetite Suppressants
Data from Case Reports
Summary of Case Reports (I)
Summary of Case Reports (II)
Echocardiographic Research Case Definition for Valvulopathy with Appetite Suppressants
Summary of CARDIA Study*
Summary of Case Reports (III)
Data from Echocardiographic Screening of Asymptomatic Patients
Overview of Surveys with Fenfluramine-Phentermine
Counts of Subjects and Cases from Echo-Prevalence Surveys
Absolute Risk of Valvulopathy from Echo-Prevalence Surveys
Absolute Risk of Valvulopathy from Echo-Based Prevalence Surveys
Relative Risk of Valvulopathy from Echo-Based Prevalence Surveys; CARDIA as Reference
Relative Risk of Aortic Valvulopathy from Echo-Based Prevalence Surveys; CARDIA as Reference
Epidemiologic Study of Valvulopathy with Fenfluramine Use in an HMO
Summary of Echo Data on Obese Subjects - Obtained Prior to Suppressant Therapy
View Adobe Acrobat Presentation
Download PowerPoint (version 7/95) Presentation
CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page
FDA/Center for Drug Evaluation and Research